PC
CLVS

Passport Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Passport Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-202,804
Closed -$12.9M – 59
2017
Q1 		$12.9M Sell
202,804
-179,010
-47% -$10.9M 0.96% 27
2016
Q4 		$17M Buy
+381,814
New +$13.4M 0.28% 31

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Passport Capital's CLVS Position: Q2 2017 in Review

Passport Capital sold out of Clovis Oncology, Inc. (CLVS) in Q2 2017, closing a stake of 202,804 shares — an estimated $12.9M sold.

Passport Capital first reported a position in CLVS in Q4 2016 and held it in 2 quarters. The position peaked at $17M in Q4 2016. 271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

  • Passport Capital reported no remaining Clovis Oncology, Inc. position as of Q2 2017 after selling out during the quarter.
  • Passport Capital sold 202,804 Clovis Oncology, Inc. shares in Q2 2017, an estimated $12.9M.
  • Passport Capital first reported a position in Clovis Oncology, Inc. in Q4 2016 and held it in 2 quarters.
  • Passport Capital's Clovis Oncology, Inc. position peaked at $17M in Q4 2016.
  • 271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on Passport Capital's 13F filing for Q2 2017, filed 14 Aug 2017.